SCHEMBL1924395

SCHEMBL1924395

Cc1ccc2c(=O)c(-c3ccccc3)cn(CC(=O)Nc3nccs3)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 6/20 0.47
▸ NPC1 O15118 5/20 0.47
▸ NPSR1 Q6W5P4 4/20 0.47
▸ MAPT P10636 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.47
▸ MEN1 O00255 4/20 0.47
▸ KMT2A Q03164 4/20 0.47
▸ KAT2A Q92830 1/20 0.46
▸ KAT2B Q92831 1/20 0.46
▸ HTT P42858 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ HPGD P15428 2/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ PKM P14618 1/20 0.45
▸ CYP1A2 P05177 2/20 0.44
▸ CYP3A4 P08684 2/20 0.44
▸ CYP2C9 P11712 2/20 0.44
▸ RXFP1 Q9HBX9 1/20 0.44
▸ NR2E3 Q9Y5X4 1/20 0.44
▸ KCNA5 P22460 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1923413 0.94 LMNA (0.48) RAB9ANPC1NPSR1MAPTALDH1A1
SCHEMBL1923888 0.91 NPC1 (0.44) RAB9ANPC1NPSR1MAPTALDH1A1
SCHEMBL1923811 0.91 USP10 (0.45) RAB9ANPC1NPSR1MAPTALDH1A1
SCHEMBL1923683 0.89 RAB9A (0.49) RAB9ANPC1NPSR1MAPTALDH1A1
SCHEMBL1923646 0.86 USP10 (0.46) RAB9AMAPTMEN1KMT2AHTT
SCHEMBL1923590 0.85 USP10 (0.45) MAPTKMT2AHTTLMNASMN1; SMN2
SCHEMBL1923474 0.85 KMT2A (0.47) RAB9ANPC1NPSR1MAPTMEN1
SCHEMBL1923836 0.83 MEN1 (0.50) RAB9ANPC1MEN1KMT2AHTT
SCHEMBL1924700 0.83 MAPK8 (0.46) RAB9ANPSR1MAPTALDH1A1MEN1
SCHEMBL1923602 0.82 CPT2 (0.55) MAPTALDH1A1MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2064185-B1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INT (ES) 2011-06-08 — — EP claimed
US-20100168099-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL, S.A. (ES) 2010-07-01 — — US claimed
CN-101522630-A 1H-quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions FERRER INT (ES) 2009-09-02 — — CN claimed
EP-2064185-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS Ferrer Internacional, S.A. (ES) 2009-06-03 — — EP claimed
WO-2008017710-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL S.A. (ES) 2008-02-14 — — WO claimed
EP-1886996-A1 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2008-02-13 — — EP claimed
EP-2064185-B1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INT (ES) 2011-06-08 — — EP disclosed
US-20100168099-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL, S.A. (ES) 2010-07-01 — — US disclosed
CN-101522630-A 1H-quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions FERRER INT (ES) 2009-09-02 — — CN disclosed
EP-2064185-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS Ferrer Internacional, S.A. (ES) 2009-06-03 — — EP disclosed
WO-2008017710-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL S.A. (ES) 2008-02-14 — — WO disclosed
EP-1886996-A1 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2008-02-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168099-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS GABRA1, GABRA4, GABRA2 RAB9A 962/4885NPC1 2139/4885NPSR1 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback